## 3 Results  
Of the fifty-four eligible patients, four decided not to participate, resulting in their exclusion. Ultimately, 50 patients were included in the study and randomly assigned to two groups without follow-up losses: the treatment group, with 25 participants, and the inactive TENS sham group (sham treatment) with 25 participants. Figure 4 shows the sociodemographic data of the patients. A. Immediate Effects of the Treatment  
In the first session, the immediate effects of the treatment with TENS were assessed with the VAS-X, Xerostomia Inventory (XI), sialometry, and OHIP-14 scales (Table 1). The specific results are described below. Figure 4: Sociodemographic and Clinical Characteristics of the participants. No radiotherapy patients participated in this study. Although it was not an exclusion criterion, no patients undergoing radiotherapy were included during the study. B. Interpretation of the Comparison between Groups:  
The comparison between the \"Treatment\" and \"Sham\" groups showed statistically significant differences (_p_ < 0.01). With respect to the sialometry results (mm), a significant difference was observed between groups (_p_ = 0.02), with a stronger increase in the measurement of salivary flow. In the XI test, the difference between the groups was highly significant (_p_ < 0.001), and lastly, with regard to OHIP-14, neither group showed significant changes in the post-session scores, which suggests that the impact on the perception of oral health was not considerable, although differentially significant at the statistical level. C. In the treatment group, the TENS treatment led to significant changes in the perception of xerostonia (VAS-X and XI (Thomson)) and sialometry, and a tendency for quality of life to improve was also observed (OHIP-14). In the treatment group, a progressive improvement was observed after the three treatment sessions. The initial VA-X scores significantly decreased from 7.52 \(\pm\) 1.92 in the first session to 6.84 \(\pm\) 1.84 after the third session (_p_ < 0.001). Similarly, the production of saliva significantly increased from 21.00 \(\pm\) 16.38 mm to 27.68 \(\pm\) 29.44 mm after the first session, showing a continuous increase in posterior sessions (_p_ < 0.001) (Figure 5). As for the subjective perception of mouth dryness, the Xerostonia Inventory (XI) (Thomson) decreased from 36.88 \(\pm\) 7.78 to 35.60 \(\pm\) 7.42 after the sessions (_p_ = 0.01). \begin{table}
\begin{tabular}{c c c c c} \hline
**Group** & **Test** & **Baseline (Mean \(\pm\) SD)** & \begin{tabular}{c} **Post-Session** \\ **(Mean \(\pm\) SD)** \\ \end{tabular} & \begin{tabular}{c} _p-Value** \\ **(Baseline vs. Post)** \\ \end{tabular} \\ \hline Treatment & VAS-X & 7.52 \(\pm\) 1.92 points & 6.84 \(\pm\) 1.84 points & \textless{}0.001 \\ \hline  & Salometry, mm & 21.00 \(\pm\) 16.38 mm & 27.68 \(\pm\) 29.44 mm & \textless{}0.001 \\ \hline  & \
\begin{tabular}{c} Xerostonia \\ Inventory (XI) \\ \end{tabular} & 36.88 \(\pm\) 7.78 points & 35.60 \(\pm\) 7.42 points & 0.01 \\ \hline Sham & VAS-X & 5.24 \(\pm\) 2.13 points & 5.04 \(\pm\) 2.15 points & 0.04 \\ \hline  & Salometry, mm & 29.56 \(\pm\) 16.55 mm & 29.80 \(\pm\) 16.51 mm & 0.68 \\ \hline  &
\begin{tabular}{c} Xerostonia \\ Inventory (XI) \\ \end{tabular} & 28.74 \(\pm\) 9.30 points & 28.74 \(\pm\) 9.30 points & Not sig. \\ \hline \end{tabular}
\end{table} 
Table 1: Immediate effects of the treatment with TENS as assessed with the VAS-X, sialometry, and Xerostonia Inventory (XI). Figure 5: Distribution of the Visual Analog Scale (EVA) scores for each session (Session 1; Session 2; Session 3) in the treatment group. Although the quality of life measured with the OHIP-14 was not significant (30.72 \(\pm\) 11.73 to 30.12 \(\pm\) 11.19, \(p\) = 0.06), the data showed a cumulative positive impact of the treatment in the treatment group.